Education
About Us
Working with TipRanks
Follow Us
Option Care Health (OPCH)
NASDAQ:OPCH
OPCH Analyst Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
OPCH Stock 12 Month Forecast
Average Price Target
$36.50
▲(40.22% Upside)
| Highest Price Target$40.00 | Average Price Target$36.50 | Lowest Price Target$30.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Truist Financial
$40
Buy
53.67%
Upside
Reiterated
10/31/25
TR | OpenAI - 4o
$31→$28
Hold
7.57%
Upside
Downgraded
10/31/25
AI Generated ArticleAI Generated Article
Barrington
$38
Buy
45.99%
Upside
Reiterated
10/31/25
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and Option Care Health (NASDAQ: OPCH)We are maintaining our OUTPERFORM investment rating on OPCH and our price target remains $38. We arrive at our price target by attaching a 13.5x multiple to our 2026 adjusted EBITDA estimate.
Citizens JMP
$36
Buy
38.30%
Upside
Reiterated
10/31/25
William Blair
―
Buy
―
Reiterated
10/30/25
Option Care Health: Strong Financial Performance and Strategic Positioning Justify Buy RatingWe will update our model and estimates after the conference call. Care delivered results ahead of expectations for the 23rd straight quarter, with revenue, adjusted EBITDA, and adjusted EPS all beating our/Street estimates. Management again raised its full-year guidance and now expects revenue of $5.60 billion to $5.65 billion (up from $5.50 billion to $5.65 billion), adjusted EBITDA of $468 million to $473 million (narrowed from $465 million to $475 million), adjusted EPS of $1.68 to $1.72 (up from $1.65 to $1.72), and operating cash flow of at least $320 million (unchanged). On balance, this looks to be another solid update for Option Care amid the ongoing Stelara headwind, which we look to the call for an update on (previously guided to a $60 million to $70 million gross profit impact in 2025).
Morgan Stanley
$35
Buy
34.46%
Upside
Initiated
10/17/25
TD Cowen
$30
Hold
15.25%
Upside
Initiated
10/02/25
Option Care Health: Strong Market Position and Financials Balanced by Lack of Near-Term CatalystsWe initiate coverage of Option Care Health (OPCH) with a Hold rating and $30 PT. OPCH is the leading home and alt. site infusion provider with exposure to specialty and a strong B/S to support cap. deployment. While we think OPCH can hit its LT growth targets, we also think this is baked into consensus ests. Combining this with a lack of obvious catalysts, we believe a Hold rating is appropriate.
UBS
$40
Buy
53.67%
Upside
Reiterated
09/23/25
Bank of America Securities
―
Buy
―
Reiterated
05/14/25
J.P. Morgan
―
Buy
―
Reiterated
04/11/25
Jefferies
$40
Buy
53.67%
Upside
Reiterated
04/11/25
Goldman Sachs
$25→$35
Hold
34.46%
Upside
Reiterated
02/28/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Truist Financial
$40
Buy
53.67%
Upside
Reiterated
10/31/25
TR | OpenAI - 4o
$31→$28
Hold
7.57%
Upside
Downgraded
10/31/25
AI Generated ArticleAI Generated Article
Barrington
$38
Buy
45.99%
Upside
Reiterated
10/31/25
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and Option Care Health (NASDAQ: OPCH)We are maintaining our OUTPERFORM investment rating on OPCH and our price target remains $38. We arrive at our price target by attaching a 13.5x multiple to our 2026 adjusted EBITDA estimate.
Citizens JMP
$36
Buy
38.30%
Upside
Reiterated
10/31/25
William Blair
―
Buy
―
Reiterated
10/30/25
Option Care Health: Strong Financial Performance and Strategic Positioning Justify Buy RatingWe will update our model and estimates after the conference call. Care delivered results ahead of expectations for the 23rd straight quarter, with revenue, adjusted EBITDA, and adjusted EPS all beating our/Street estimates. Management again raised its full-year guidance and now expects revenue of $5.60 billion to $5.65 billion (up from $5.50 billion to $5.65 billion), adjusted EBITDA of $468 million to $473 million (narrowed from $465 million to $475 million), adjusted EPS of $1.68 to $1.72 (up from $1.65 to $1.72), and operating cash flow of at least $320 million (unchanged). On balance, this looks to be another solid update for Option Care amid the ongoing Stelara headwind, which we look to the call for an update on (previously guided to a $60 million to $70 million gross profit impact in 2025).
Morgan Stanley
$35
Buy
34.46%
Upside
Initiated
10/17/25
TD Cowen
$30
Hold
15.25%
Upside
Initiated
10/02/25
Option Care Health: Strong Market Position and Financials Balanced by Lack of Near-Term CatalystsWe initiate coverage of Option Care Health (OPCH) with a Hold rating and $30 PT. OPCH is the leading home and alt. site infusion provider with exposure to specialty and a strong B/S to support cap. deployment. While we think OPCH can hit its LT growth targets, we also think this is baked into consensus ests. Combining this with a lack of obvious catalysts, we believe a Hold rating is appropriate.
UBS
$40
Buy
53.67%
Upside
Reiterated
09/23/25
Bank of America Securities
―
Buy
―
Reiterated
05/14/25
J.P. Morgan
―
Buy
―
Reiterated
04/11/25
Jefferies
$40
Buy
53.67%
Upside
Reiterated
04/11/25
Goldman Sachs
$25→$35
Hold
34.46%
Upside
Reiterated
02/28/25
Best Analysts Covering Option Care Health
1 Month
xxx
Success Rate
18/27 ratings generated profit
Average Return
+2.25%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +2.25% per trade.
3 Months
xxx
Success Rate
8/14 ratings generated profit
Average Return
+5.13%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +5.13% per trade.
1 Year
Success Rate
16/27 ratings generated profit
Average Return
+6.10%
reiterated a buy rating 2 days ago
Copying David S Macdonald's trades and holding each position for 1 Year would result in 59.26% of your transactions generating a profit, with an average return of +6.10% per trade.
2 Years
xxx
Success Rate
9/14 ratings generated profit
Average Return
+16.67%
reiterated a xxx
rating a year ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 64.29% of your transactions generating a profit, with an average return of +16.67% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
OPCH Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
0
0
0
0
0
Buy
28
24
19
17
10
Hold
0
0
1
3
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
24
20
20
14
Each month's total comprises the sum of three months' worth of ratings.
OPCH Financial Forecast
OPCH Stock Forecast FAQ
What is OPCH’s average 12-month price target, according to analysts?
Based on analyst ratings, Option Care Health’s 12-month average price target is 36.50.
What is OPCH’s upside potential, based on the analysts’ average price target?
Option Care Health has 40.22% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is OPCH a Buy, Sell or Hold?
Option Care Health has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
What is Option Care Health’s price target?
The average price target for Option Care Health is 36.50. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $30.00. The average price target represents 40.22% Increase from the current price of $26.03.
The highest analyst price target is $40.00 ,the lowest forecast is $30.00. The average price target represents 40.22% Increase from the current price of $26.03.
What do analysts say about Option Care Health?
Option Care Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of OPCH?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.